Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides

The Alabama Board of Medical Examiners and Medical Licensure Commission issued a warning to health care providers regarding the use of non-FDA-approved, research-grade peptides, clarifying that these substances are strictly prohibited for human administration or dispensing. For pharmacists, this notice serves as a reminder of the legal boundaries surrounding prescription-quality drugs, as the Board emphasized that physicians are legally required to purchase all prescription products and ingredients exclusively from entities permitted by the Alabama State Board of Pharmacy.¹

These research-grade substances have not been tested or reviewed for safety, and because they lack FDA oversight regarding manufacturing consistency, neither the pharmacist nor the provider can verify the contents of the vials or fully quantify the potential risks to patients.

“Peptides are signaling molecules that biology uses to turn on and off different processes; real potent in the way that it signals them,” Christopher Shade, PhD, CEO and founder of Quicksilver Scientific, said.² “We’ve been going after drugs that sort of help you stimulate these processes; maybe they get you to make some peptides, and we do supplements. It kind of encourages this stuff. But the peptides go right in. They might turn on a healing response.”

The regulatory environment for peptides is becoming increasingly complex as a peptide craze sweeps the nation, fueled by the massive market success of glucagon-like peptide-1 medications like semaglutide. Although FDA-approved peptides like insulin have been used safely for over a century, many newer compounds frequently discussed on social media for weight loss and antiaging lack rigorous human clinical data.^3,4

The Alabama Board’s recent notice makes it clear that providers cannot circumvent their duty of care by allowing mid-level practitioners, such as physician assistants or certified registered nurse practitioners, to handle these drugs, nor can they use patient waivers or consent forms to mitigate legal liability when using non-approved substances.¹

Despite these local prohibitions, a shift may be on the horizon at the federal level that could fundamentally alter the landscape for traditional pharmacy compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. An FDA advisory panel is scheduled to meet in late July 2026 to evaluate whether 7 specific peptides—including BPC-157, KPV, TB-500, and MOTs-C—should be moved from their current restricted status into the 503A Bulk Drug Substances List.³

Proponents of the shift argue that expanding legal access to these molecules, which are often used for healing injuries and metabolic health, will help move consumer demand away from the unregulated black market where products are frequently contaminated with endotoxins that can cause anaphylactic reactions.³

The scientific interest in peptides stems from their potent role as signaling molecules that can "turn on" healing responses or regulate appetite, and systematic reviews suggest they offer substantial benefits for metabolic, musculoskeletal, and behavioral health. Clinical trials demonstrated that bioactive peptides derived from milk, fish, and plants can improve muscle protein synthesis and support joint health, with some studies showing that collagen peptides significantly enhance fat-free mass and strength when combined with resistance training.^3,5

However, the medical community remains cautious because many of these substances stimulate hormone production in ways that are not yet fully understood, leading some experts to call for more data-driven oversight to prevent long-term health risks like cancer.³

As the market for these compounds continues to expand—with projections suggesting the peptide market could triple in size over the next 5 years—pharmacists find themselves at the center of a difficult enforcement environment. The FDA recently clarified that compounding pharmacies cannot bypass regulations by simply adding vitamins, such as B12, to existing formulations to claim they are not copies of commercially available drugs.

Moving forward, pharmacists must remain diligent in sourcing only high-quality, permitted materials and stay closely attuned to the evolving 503A Bulk List, as the gap between popular gray-market demand and strict regulatory standards continues to pose significant professional and legal challenges.³

“[It’s] staying with stuff that has the research, the pharmacist staying on top of regulations—when things are taken off, when things are put back on the list—and ensuring they have quality compounding pharmacists,” Shade said.⁶ “They have to make sure they go above and beyond on the testing of these to ensure they have the safety. Most of them should know that, but they just have to be super diligent and not get too crazed out with every new number that comes out.”

REFERENCES

1. Board issues official notice concerning the prescribing of non-FDA approved (research-grade) peptides. News release. Alabama Board of Medical Examiners. Accessed June 5, 2026. Https://www.albme.gov/press-release/board-issues-official-notice-concerning-the-prescribing-of-non-fda-approved-research-grade-peptides

2. Nowosielski B. Q&A: understanding the pharmaceutical community’s attention on peptides. Drug Topics. April 26, 2026. Accessed June 5, 2026. https://www.drugtopics.com/view/understanding-the-pharmaceutical-community-s-attention-on-peptides

3. Nowosielski B. FDA set to review peptide access for compounding pharmacies. Drug Topics. April 24, 2026. Accessed June 5, 2026. https://www.drugtopics.com/view/fda-set-to-review-peptide-access-for-compounding-pharmacies

4. Baptist Health. What are peptides and what's all the buzz about?. April 30, 2026. Accessed June 5, 2026. https://www.baptisthealth.com/blog/primary-care/what-are-peptides-and-whats-all-the-buzz-about

5. Zakir SK, Jawed B, Esposito JE, et al. The Role of Peptides in Nutrition: Insights into Metabolic, Musculoskeletal, and Behavioral Health: A Systematic Review. Int J Mol Sci. 2025;26(13):6043. Published 2025 Jun 24. doi:10.3390/ijms26136043

6. Nowosielski B. Q&A: pharmacists must steer patients from risky, gray-market peptides. Drug Topics. April 27, 2026. Accessed June 5, 2026. https://www.drugtopics.com/view/pharmacists-must-steer-patients-from-risky-gray-market-peptides